PurposeTo evaluate the effects of ophthalmic solutions based on sodium hyaluronate (SH) with or without taurine (TAU) in experimental dry eye disease models.MethodsRabbit corneal epithelial cells (SIRCs) were exposed to oxidative stress (1 mM H2O2) and treated with the following formulations: 0.2% SH, 0.4% SH, 0.4% SH + 0.5% TAU. Reactive oxygen species (ROS) were assessed by commercial kit (ab113851). Dry eye was induced in albino rabbits by topical application (4 times per day) of 1% atropine eye drops. Fifteen minutes after atropine instillation we treated the eyes with test formulations (0.2% SH, 0.4% SH, 0.4% SH + 0.5% TAU). The following endpoints were evaluated: tear breakup time (TBUT), Schirmer's test, ferning test, tear osmolarity. Results were compared to negative (CTR‐; normal eye) and positive control groups (CTR+; atropine‐treated eye).ResultsTaurine significantly (p < 0.01) quenched ROS production in SIRC after oxidative stress. The effect of taurine, in terms of ROS quenching, was significantly (p < 0.01) higher compared to SH‐treated cells. Topical administration of atropine in the rabbit eye significantly (p < 0.01) reduced tear volume and TBUT. Ferning test and tear osmolarity were also significantly (p < 0.01) modified by atropine treatment. All the altered parameters were significantly (p < 0.01) reversed by 0.4% SH + 0.5% TAU treatment. Furthermore, treatment with SH‐TAU formulation was more effective compared to SH formulations.ConclusionsAll together these data demonstrated that taurine has a potent antioxidant activity preventing the negative effect elicited by atropine on tear stability. Therefore, our findings support the hypothesis that the formulation containing taurine may be more useful than SH formulations in clinical practice to manage ocular surface diseases related to dry eye.
Read full abstract